ETF Holdings Breakdown of PTCT

News associated with PTCT

PTC Therapeutics (NASDAQ:PTCT) Coverage Initiated at Truist Financial

Equities researchers at Truist Financial started coverage on shares of PTC Therapeutics (NASDAQ:PTCT – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $80.00 price target on the biopharmaceutical company’s stock. Truist Financial’s target price points to a potential upside […] - 2025-06-19 05:42:49

Pallas Capital Advisors LLC Makes New $353,000 Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)

Pallas Capital Advisors LLC purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,925 shares of the biopharmaceutical company’s stock, valued at approximately $353,000. Several other institutional […] - 2025-06-13 08:38:53

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by GAMMA Investing LLC

GAMMA Investing LLC lifted its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 9,393.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 48,514 shares of the biopharmaceutical company’s stock after acquiring an additional 48,003 shares during the quarter. GAMMA Investing LLC’s holdings […] - 2025-06-13 07:36:51

Universal Beteiligungs und Servicegesellschaft mbH Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 108,345 shares of the biopharmaceutical company’s stock, valued at approximately $4,891,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.14% of PTC […] - 2025-06-02 09:10:57

Wells Fargo & Company Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $74.00

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) had its price target hoisted by equities research analysts at Wells Fargo & Company from $68.00 to $74.00 in a report released on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price target suggests a potential upside of […] - 2025-05-29 05:31:00

PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation, eight have assigned a buy recommendation and one has assigned a […] - 2025-05-28 07:46:51

PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up After Earnings Beat

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $36.19, but opened at $39.40. PTC Therapeutics shares last traded at $39.92, with a volume of 455,281 shares trading hands. The biopharmaceutical company reported $10.04 […] - 2025-05-09 05:20:49

Analysts Set PTC Therapeutics, Inc. (NASDAQ:PTCT) PT at $63.92

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) have earned an average rating of “Moderate Buy” from the fifteen brokerages that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have assigned a buy rating and one has […] - 2025-05-06 05:30:48

48,728 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the fourth quarter, Holdings Channel reports. The firm acquired 48,728 shares of the biopharmaceutical company’s stock, valued at approximately $2,200,000. Several other institutional investors have also added to or reduced their stakes in the business. Smartleaf Asset Management […] - 2025-05-01 08:01:04

Federated Hermes Inc. Buys New Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT)

Federated Hermes Inc. purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 47,828 shares of the biopharmaceutical company’s stock, valued at approximately $2,159,000. A number of other hedge funds and other institutional investors have also recently modified their holdings of […] - 2025-04-14 08:15:06

PTC Therapeutics, Inc. (NASDAQ:PTCT) Position Reduced by Prudential Financial Inc.

Prudential Financial Inc. trimmed its position in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 5.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 5,620 shares of the biopharmaceutical company’s stock after selling 330 shares during the quarter. Prudential Financial Inc.’s holdings in PTC Therapeutics were worth $254,000 at the end of the most […] - 2025-04-11 08:03:01

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Corebridge Financial Inc.

Corebridge Financial Inc. lowered its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 7.0% during the fourth quarter, Holdings Channel reports. The fund owned 37,864 shares of the biopharmaceutical company’s stock after selling 2,859 shares during the quarter. Corebridge Financial Inc.’s holdings in PTC Therapeutics were worth $1,709,000 at the end […] - 2025-04-03 08:15:12

KLP Kapitalforvaltning AS Invests $646,000 in PTC Therapeutics, Inc. (NASDAQ:PTCT)

KLP Kapitalforvaltning AS bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 14,300 shares of the biopharmaceutical company’s stock, valued at approximately $646,000. Other large investors have also recently added to or […] - 2025-04-02 08:16:57

PTC Therapeutics (NASDAQ:PTCT) Stock Price Down 8.8% After Analyst Downgrade

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price dropped 8.8% during trading on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $78.00 to $75.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. PTC Therapeutics traded as low as $45.40 and last traded at […] - 2025-04-02 05:12:49

JPMorgan Chase & Co. Issues Pessimistic Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price

PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective cut by JPMorgan Chase & Co. from $78.00 to $75.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. PTCT has been the subject of a number of other research reports. Cantor […] - 2025-04-01 06:06:52

Natixis Advisors LLC Makes New $544,000 Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)

Natixis Advisors LLC purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 12,060 shares of the biopharmaceutical company’s stock, valued at approximately $544,000. A number of other […] - 2025-03-28 08:04:51

Cibc World Markets Corp Makes New Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)

Cibc World Markets Corp acquired a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 7,127 shares of the biopharmaceutical company’s stock, valued at approximately $322,000. Other institutional investors also […] - 2025-03-25 08:16:59

Zurcher Kantonalbank Zurich Cantonalbank Buys 3,450 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)

Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 22.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,863 shares of the biopharmaceutical company’s stock after acquiring an additional 3,450 shares during the […] - 2025-03-21 08:11:01

Arizona State Retirement System Grows Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)

Arizona State Retirement System grew its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 1.1% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 20,095 shares of the biopharmaceutical company’s stock after purchasing an additional 219 shares during the period. Arizona State Retirement System’s […] - 2025-03-14 08:12:51

PTC Therapeutics (NASDAQ:PTCT) Raised to “Neutral” at Bank of America

Bank of America upgraded shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) from an underperform rating to a neutral rating in a research note published on Tuesday morning, MarketBeat Ratings reports. They currently have $55.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $41.00. Several other brokerages have also […] - 2025-03-12 06:50:46

PTC Therapeutics (NASDAQ:PTCT) Research Coverage Started at Scotiabank

Scotiabank initiated coverage on shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) in a research report sent to investors on Friday, Marketbeat.com reports. The firm issued a sector perform rating and a $55.00 price objective on the biopharmaceutical company’s stock. A number of other equities analysts have also commented on PTCT. Royal Bank of Canada […] - 2025-03-10 06:28:54

Y Intercept Hong Kong Ltd Sells 2,805 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)

Y Intercept Hong Kong Ltd lowered its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 20.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 11,024 shares of the biopharmaceutical company’s stock after selling 2,805 shares during the quarter. Y Intercept […] - 2025-03-03 09:00:50

Handelsbanken Fonder AB Cuts Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)

Handelsbanken Fonder AB cut its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 3.6% in the 4th quarter, Holdings Channel reports. The fund owned 23,800 shares of the biopharmaceutical company’s stock after selling 900 shares during the quarter. Handelsbanken Fonder AB’s holdings in PTC Therapeutics were worth $1,074,000 at the end of the […] - 2025-02-28 09:24:52

Venturi Wealth Management LLC Buys Shares of 1,500 PTC Therapeutics, Inc. (NASDAQ:PTCT)

Venturi Wealth Management LLC bought a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,500 shares of the biopharmaceutical company’s stock, valued at approximately $68,000. Other institutional investors and hedge funds also […] - 2025-02-25 09:01:00

Vontobel Holding Ltd. Takes $521,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)

Vontobel Holding Ltd. acquired a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) in the 4th quarter, HoldingsChannel.com reports. The fund acquired 11,532 shares of the biopharmaceutical company’s stock, valued at approximately $521,000. Several other large investors have also recently bought and sold shares of PTCT. Point72 Asset Management L.P. raised its position […] - 2025-02-20 09:48:49

Royal Bank of Canada Forecasts Strong Price Appreciation for PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) had its price objective hoisted by Royal Bank of Canada from $60.00 to $63.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s target price suggests a potential upside […] - 2025-02-20 08:58:59

StockNews.com Downgrades PTC Therapeutics (NASDAQ:PTCT) to Hold

StockNews.com lowered shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) from a buy rating to a hold rating in a research note published on Monday morning. Several other analysts have also recently issued reports on PTCT. Morgan Stanley raised PTC Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price […] - 2025-02-18 06:44:48

Apollon Wealth Management LLC Has $399,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)

Apollon Wealth Management LLC lowered its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 50.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 8,839 shares of the biopharmaceutical company’s stock after selling 8,839 shares during the quarter. Apollon Wealth […] - 2025-02-14 08:36:51

KBC Group NV Has $137,000 Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)

KBC Group NV raised its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 36.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,045 shares of the biopharmaceutical company’s stock after purchasing an additional 813 shares during the quarter. KBC Group NV’s […] - 2025-02-07 08:47:24

PTC Therapeutics (NASDAQ:PTCT) Shares Up 6.1% Following Analyst Upgrade

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) shot up 6.1% during trading on Monday after Cantor Fitzgerald raised their price target on the stock from $76.00 to $113.00. Cantor Fitzgerald currently has an overweight rating on the stock. PTC Therapeutics traded as high as $48.44 and last traded at $48.70. 85,379 shares […] - 2025-02-05 06:42:55

PTCT institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	49,626	USD 2,458,968 1.3%
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	7,782	USD 385,598
2025-06-26	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	98,114	USD 4,861,549
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	39,552	USD 1,959,802
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	39,552	USD 1,959,802
2025-06-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	276	USD 13,676
Total =		234,902	USD 11,639,395

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer